Cypherpunk Technologies (NASDAQ:CYPH – Get Free Report) Director Thomas John Dietz sold 20,000 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $1.72, for a total transaction of $34,400.00. Following the sale, the director directly owned 132,500 shares in the company, valued at approximately $227,900. This represents a 13.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Cypherpunk Technologies Stock Up 16.0%
CYPH stock traded up $0.26 during trading on Thursday, hitting $1.89. The company had a trading volume of 14,437,919 shares, compared to its average volume of 3,801,312. The stock has a market cap of $203.67 million, a price-to-earnings ratio of 3.37 and a beta of 0.09. Cypherpunk Technologies has a 12 month low of $0.27 and a 12 month high of $3.70. The firm has a 50-day moving average price of $0.77 and a 200-day moving average price of $0.81.
Cypherpunk Technologies (NASDAQ:CYPH – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.18 earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Cypherpunk Technologies
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on CYPH. Wall Street Zen upgraded shares of Cypherpunk Technologies from a “sell” rating to a “hold” rating in a report on Saturday, July 4th. Weiss Ratings upgraded shares of Cypherpunk Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $1.60 price target on shares of Cypherpunk Technologies in a research note on Thursday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $1.60.
View Our Latest Report on CYPH
About Cypherpunk Technologies
Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.
DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.
Read More
- Five stocks we like better than Cypherpunk Technologies
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Cypherpunk Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cypherpunk Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
